 Paula Riggs
Concepts (278)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Substance-Related Disorders | 36 | 2023 | 942 | 4.890 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 18 | 2015 | 363 | 2.000 |
Why?
| | Marijuana Smoking | 5 | 2023 | 224 | 1.590 |
Why?
| | Central Nervous System Stimulants | 9 | 2013 | 140 | 1.420 |
Why?
| | Cannabis | 4 | 2023 | 383 | 1.230 |
Why?
| | Prescription Drug Misuse | 3 | 2019 | 38 | 1.190 |
Why?
| | Fluoxetine | 3 | 2019 | 46 | 1.050 |
Why?
| | Prescription Drugs | 2 | 2019 | 116 | 1.040 |
Why?
| | Conduct Disorder | 6 | 2012 | 193 | 0.930 |
Why?
| | Adolescent Behavior | 7 | 2016 | 486 | 0.910 |
Why?
| | Adolescent | 46 | 2023 | 17800 | 0.890 |
Why?
| | Substance Abuse, Intravenous | 2 | 2016 | 100 | 0.890 |
Why?
| | Opioid-Related Disorders | 3 | 2019 | 413 | 0.810 |
Why?
| | Escherichia coli | 10 | 2021 | 723 | 0.790 |
Why?
| | Problem Behavior | 1 | 2022 | 86 | 0.760 |
Why?
| | Hallucinogens | 1 | 2023 | 72 | 0.750 |
Why?
| | Mental Disorders | 6 | 2016 | 889 | 0.720 |
Why?
| | Methylphenidate | 6 | 2012 | 36 | 0.700 |
Why?
| | Recombinant Fusion Proteins | 9 | 2021 | 613 | 0.680 |
Why?
| | Psychiatry | 1 | 2022 | 154 | 0.680 |
Why?
| | Escherichia coli Proteins | 8 | 2021 | 162 | 0.680 |
Why?
| | Maltose-Binding Proteins | 7 | 2021 | 10 | 0.680 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2019 | 227 | 0.530 |
Why?
| | Depression | 2 | 2019 | 1133 | 0.530 |
Why?
| | School Health Services | 2 | 2016 | 206 | 0.520 |
Why?
| | Health Care Reform | 1 | 2016 | 92 | 0.500 |
Why?
| | Acetic Acid | 1 | 2015 | 16 | 0.500 |
Why?
| | Honey | 1 | 2015 | 8 | 0.500 |
Why?
| | Early Medical Intervention | 1 | 2016 | 52 | 0.490 |
Why?
| | Depressive Disorder, Major | 4 | 2011 | 301 | 0.450 |
Why?
| | Public Health | 2 | 2016 | 433 | 0.450 |
Why?
| | Homeless Youth | 1 | 2013 | 15 | 0.440 |
Why?
| | Carrier Proteins | 6 | 2001 | 694 | 0.440 |
Why?
| | Academies and Institutes | 1 | 2013 | 44 | 0.440 |
Why?
| | Analgesics, Opioid | 2 | 2019 | 771 | 0.420 |
Why?
| | Awards and Prizes | 1 | 2013 | 56 | 0.420 |
Why?
| | Humans | 53 | 2023 | 114045 | 0.410 |
Why?
| | Evidence-Based Medicine | 1 | 2016 | 662 | 0.400 |
Why?
| | Drug Overdose | 1 | 2016 | 292 | 0.400 |
Why?
| | Periodicals as Topic | 1 | 2013 | 180 | 0.370 |
Why?
| | Pemoline | 2 | 2004 | 5 | 0.370 |
Why?
| | Empirical Research | 1 | 2010 | 21 | 0.350 |
Why?
| | Mutant Proteins | 1 | 2010 | 95 | 0.340 |
Why?
| | Research Subjects | 1 | 2010 | 40 | 0.340 |
Why?
| | Psychology, Adolescent | 2 | 2007 | 63 | 0.320 |
Why?
| | Mutation, Missense | 1 | 2010 | 294 | 0.300 |
Why?
| | Diagnosis, Dual (Psychiatry) | 6 | 2015 | 35 | 0.300 |
Why?
| | Neurobiology | 1 | 2007 | 16 | 0.290 |
Why?
| | Education, Continuing | 1 | 2008 | 39 | 0.290 |
Why?
| | Mental Health | 2 | 2023 | 559 | 0.290 |
Why?
| | Drug Therapy | 1 | 2008 | 74 | 0.280 |
Why?
| | Family | 5 | 2022 | 589 | 0.270 |
Why?
| | Comorbidity | 8 | 2016 | 1447 | 0.260 |
Why?
| | Drug Prescriptions | 1 | 2008 | 237 | 0.260 |
Why?
| | Male | 31 | 2021 | 55396 | 0.250 |
Why?
| | Protein Engineering | 2 | 2010 | 98 | 0.240 |
Why?
| | Personality Disorders | 3 | 2006 | 67 | 0.240 |
Why?
| | Juvenile Delinquency | 4 | 2004 | 103 | 0.240 |
Why?
| | Depressive Disorder | 3 | 1997 | 330 | 0.240 |
Why?
| | Protein Disulfide-Isomerases | 3 | 2015 | 8 | 0.240 |
Why?
| | Research | 1 | 2007 | 389 | 0.230 |
Why?
| | Linear Models | 2 | 2018 | 768 | 0.230 |
Why?
| | Schizophrenia | 1 | 2008 | 412 | 0.220 |
Why?
| | Combined Modality Therapy | 6 | 2011 | 1117 | 0.220 |
Why?
| | Young Adult | 6 | 2019 | 10444 | 0.220 |
Why?
| | Protein Folding | 3 | 2015 | 239 | 0.210 |
Why?
| | Tobacco Use Disorder | 3 | 2011 | 234 | 0.210 |
Why?
| | Adolescent Health | 1 | 2022 | 37 | 0.200 |
Why?
| | Oxidoreductases | 2 | 2015 | 89 | 0.200 |
Why?
| | Female | 21 | 2017 | 59324 | 0.190 |
Why?
| | Mental Health Services | 1 | 2005 | 316 | 0.190 |
Why?
| | Adult | 13 | 2021 | 30375 | 0.190 |
Why?
| | Child | 7 | 2023 | 18401 | 0.190 |
Why?
| | Stress Disorders, Post-Traumatic | 2 | 2021 | 757 | 0.180 |
Why?
| | Genetic Vectors | 6 | 2001 | 287 | 0.180 |
Why?
| | Treatment Outcome | 6 | 2016 | 9049 | 0.170 |
Why?
| | Sex Factors | 5 | 2017 | 1706 | 0.170 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2008 | 1168 | 0.170 |
Why?
| | Oxidation-Reduction | 3 | 2019 | 917 | 0.170 |
Why?
| | Prokaryotic Cells | 1 | 2019 | 5 | 0.170 |
Why?
| | Practice Patterns, Physicians' | 1 | 2008 | 1175 | 0.170 |
Why?
| | Epitopes | 1 | 2021 | 434 | 0.160 |
Why?
| | Longitudinal Studies | 2 | 2023 | 2384 | 0.160 |
Why?
| | Prescriptions | 1 | 2019 | 60 | 0.160 |
Why?
| | Bupropion | 1 | 1998 | 39 | 0.160 |
Why?
| | Dopamine Uptake Inhibitors | 1 | 1998 | 54 | 0.150 |
Why?
| | Disulfides | 3 | 2015 | 90 | 0.150 |
Why?
| | Deoxyribonucleases, Type II Site-Specific | 1 | 1997 | 16 | 0.150 |
Why?
| | Green Fluorescent Proteins | 1 | 2019 | 370 | 0.150 |
Why?
| | Attention Deficit and Disruptive Behavior Disorders | 1 | 1998 | 56 | 0.140 |
Why?
| | Motivational Interviewing | 1 | 2019 | 88 | 0.140 |
Why?
| | Cytoplasm | 2 | 2015 | 255 | 0.140 |
Why?
| | Antisocial Personality Disorder | 1 | 1998 | 156 | 0.140 |
Why?
| | Clonidine | 1 | 1996 | 22 | 0.140 |
Why?
| | Bayes Theorem | 1 | 2018 | 327 | 0.130 |
Why?
| | Molecular Sequence Data | 6 | 2010 | 2783 | 0.130 |
Why?
| | Genes, Reporter | 1 | 1997 | 256 | 0.130 |
Why?
| | Chromatography, Affinity | 4 | 2001 | 80 | 0.130 |
Why?
| | Solubility | 2 | 2010 | 223 | 0.130 |
Why?
| | Organisms, Genetically Modified | 1 | 2015 | 15 | 0.130 |
Why?
| | Sulfenic Acids | 1 | 2015 | 7 | 0.130 |
Why?
| | Statistical Distributions | 1 | 2015 | 7 | 0.130 |
Why?
| | Chromatography, Ion Exchange | 3 | 2001 | 48 | 0.120 |
Why?
| | Problem Solving | 2 | 2006 | 145 | 0.120 |
Why?
| | Antidepressive Agents | 1 | 1997 | 195 | 0.120 |
Why?
| | Social Behavior Disorders | 1 | 1995 | 14 | 0.120 |
Why?
| | Psychotropic Drugs | 1 | 1995 | 54 | 0.120 |
Why?
| | Risk Factors | 2 | 2023 | 8614 | 0.120 |
Why?
| | Behavior, Addictive | 1 | 2015 | 81 | 0.110 |
Why?
| | Placebos | 2 | 2011 | 197 | 0.110 |
Why?
| | Antibody Formation | 1 | 2015 | 266 | 0.110 |
Why?
| | Delayed-Action Preparations | 2 | 2011 | 158 | 0.110 |
Why?
| | Risk | 1 | 2016 | 810 | 0.110 |
Why?
| | Interpersonal Relations | 2 | 2006 | 338 | 0.110 |
Why?
| | Cloning, Molecular | 5 | 2000 | 522 | 0.110 |
Why?
| | Smoking | 3 | 2011 | 1382 | 0.110 |
Why?
| | Models, Molecular | 3 | 2010 | 1368 | 0.100 |
Why?
| | Colorado | 4 | 2017 | 4090 | 0.100 |
Why?
| | Models, Statistical | 1 | 2015 | 595 | 0.100 |
Why?
| | Immunoglobulin G | 1 | 2015 | 766 | 0.090 |
Why?
| | Behavior Therapy | 3 | 2015 | 225 | 0.090 |
Why?
| | Crystallography, X-Ray | 3 | 2021 | 402 | 0.090 |
Why?
| | DNA | 1 | 1997 | 1350 | 0.090 |
Why?
| | Protein Structure, Tertiary | 2 | 2010 | 796 | 0.090 |
Why?
| | Statistics, Nonparametric | 2 | 2004 | 384 | 0.090 |
Why?
| | Propylamines | 1 | 2010 | 11 | 0.090 |
Why?
| | Alcoholic Beverages | 1 | 2010 | 17 | 0.090 |
Why?
| | Periplasmic Proteins | 1 | 2009 | 3 | 0.090 |
Why?
| | Bacteroides fragilis | 1 | 2009 | 11 | 0.090 |
Why?
| | Polysaccharides | 1 | 2010 | 78 | 0.080 |
Why?
| | Psychiatric Status Rating Scales | 4 | 2011 | 481 | 0.080 |
Why?
| | Amino Acid Substitution | 1 | 2010 | 261 | 0.080 |
Why?
| | Protein Structure, Secondary | 1 | 2010 | 325 | 0.080 |
Why?
| | Alcohol-Related Disorders | 2 | 2011 | 113 | 0.080 |
Why?
| | Epidemiologic Studies | 1 | 2008 | 57 | 0.070 |
Why?
| | Harm Reduction | 1 | 2007 | 24 | 0.070 |
Why?
| | Plasmids | 4 | 2015 | 343 | 0.070 |
Why?
| | Amino Acid Sequence | 2 | 2010 | 1981 | 0.070 |
Why?
| | Adaptation, Psychological | 1 | 2011 | 545 | 0.070 |
Why?
| | Base Sequence | 4 | 2000 | 2114 | 0.070 |
Why?
| | Kinetics | 1 | 2010 | 1547 | 0.070 |
Why?
| | Education, Medical, Continuing | 1 | 2008 | 115 | 0.070 |
Why?
| | Citalopram | 1 | 2006 | 28 | 0.070 |
Why?
| | Health Surveys | 1 | 2008 | 441 | 0.060 |
Why?
| | Marijuana Abuse | 2 | 2005 | 211 | 0.060 |
Why?
| | Mutation | 2 | 2015 | 3338 | 0.060 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2008 | 239 | 0.060 |
Why?
| | Patient Selection | 1 | 2009 | 629 | 0.060 |
Why?
| | Pilot Projects | 2 | 2000 | 1360 | 0.060 |
Why?
| | Aged | 2 | 2016 | 18969 | 0.060 |
Why?
| | Alcohol Drinking | 2 | 2015 | 650 | 0.060 |
Why?
| | Managed Care Programs | 1 | 2005 | 133 | 0.060 |
Why?
| | Middle Aged | 3 | 2016 | 26605 | 0.060 |
Why?
| | Motivation | 2 | 2010 | 488 | 0.060 |
Why?
| | Age of Onset | 1 | 2005 | 444 | 0.060 |
Why?
| | Research Design | 3 | 2018 | 919 | 0.050 |
Why?
| | Patient Education as Topic | 1 | 2008 | 666 | 0.050 |
Why?
| | Narcotics | 1 | 2003 | 44 | 0.050 |
Why?
| | Child, Preschool | 1 | 1996 | 9114 | 0.050 |
Why?
| | Severity of Illness Index | 2 | 2012 | 2537 | 0.050 |
Why?
| | Child Behavior | 1 | 2004 | 220 | 0.050 |
Why?
| | Recombinant Proteins | 3 | 2012 | 1228 | 0.050 |
Why?
| | Osmosis | 2 | 2012 | 15 | 0.050 |
Why?
| | Safety | 1 | 2004 | 298 | 0.050 |
Why?
| | Narcotic Antagonists | 1 | 2003 | 135 | 0.050 |
Why?
| | Alkaline Phosphatase | 2 | 2015 | 142 | 0.050 |
Why?
| | Periplasmic Binding Proteins | 1 | 2001 | 14 | 0.050 |
Why?
| | Periplasm | 1 | 2001 | 10 | 0.050 |
Why?
| | Health Promotion | 1 | 2007 | 675 | 0.050 |
Why?
| | Drug Compounding | 1 | 2021 | 89 | 0.040 |
Why?
| | Enteropeptidase | 1 | 2000 | 2 | 0.040 |
Why?
| | Amylose | 1 | 2000 | 4 | 0.040 |
Why?
| | Maltose | 1 | 2000 | 5 | 0.040 |
Why?
| | Factor Xa | 1 | 2000 | 32 | 0.040 |
Why?
| | Protein Denaturation | 1 | 2000 | 68 | 0.040 |
Why?
| | Durapatite | 1 | 2000 | 35 | 0.040 |
Why?
| | Parent-Child Relations | 3 | 2006 | 235 | 0.040 |
Why?
| | Administration, Oral | 2 | 2012 | 725 | 0.040 |
Why?
| | Cross-Over Studies | 1 | 2021 | 439 | 0.040 |
Why?
| | Referral and Consultation | 2 | 2009 | 632 | 0.040 |
Why?
| | Molecular Imaging | 1 | 2019 | 50 | 0.040 |
Why?
| | Personality Assessment | 2 | 1997 | 77 | 0.040 |
Why?
| | Genetic Engineering | 1 | 2019 | 80 | 0.040 |
Why?
| | Protein Processing, Post-Translational | 1 | 2001 | 399 | 0.040 |
Why?
| | Cohort Studies | 2 | 2005 | 4883 | 0.040 |
Why?
| | Genes, Bacterial | 2 | 1989 | 157 | 0.040 |
Why?
| | Monosaccharide Transport Proteins | 2 | 1988 | 45 | 0.040 |
Why?
| | Chromatography, Liquid | 1 | 2000 | 345 | 0.040 |
Why?
| | Biosensing Techniques | 1 | 2019 | 100 | 0.040 |
Why?
| | ATP-Binding Cassette Transporters | 2 | 1988 | 122 | 0.040 |
Why?
| | Hydrogen Peroxide | 1 | 2019 | 288 | 0.040 |
Why?
| | Likelihood Functions | 1 | 2018 | 126 | 0.040 |
Why?
| | Stress, Psychological | 1 | 2005 | 944 | 0.040 |
Why?
| | Magnesium | 1 | 1997 | 144 | 0.030 |
Why?
| | DNA, Recombinant | 1 | 1997 | 41 | 0.030 |
Why?
| | Aged, 80 and over | 1 | 2008 | 6306 | 0.030 |
Why?
| | Substrate Specificity | 1 | 1997 | 350 | 0.030 |
Why?
| | Mutagenesis, Site-Directed | 1 | 1997 | 345 | 0.030 |
Why?
| | Catalysis | 1 | 1997 | 289 | 0.030 |
Why?
| | Prevalence | 2 | 2017 | 2247 | 0.030 |
Why?
| | Child Behavior Disorders | 1 | 1997 | 131 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2003 | 1381 | 0.030 |
Why?
| | Ribonuclease, Pancreatic | 1 | 2015 | 11 | 0.030 |
Why?
| | Glycosylation | 1 | 2015 | 130 | 0.030 |
Why?
| | Surface Plasmon Resonance | 1 | 2015 | 81 | 0.030 |
Why?
| | Recurrence | 1 | 1998 | 925 | 0.030 |
Why?
| | Psychotherapy | 2 | 2006 | 149 | 0.030 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2015 | 315 | 0.030 |
Why?
| | Personality Inventory | 1 | 1995 | 130 | 0.030 |
Why?
| | Stochastic Processes | 1 | 2015 | 62 | 0.030 |
Why?
| | Protein Conformation | 1 | 1997 | 803 | 0.030 |
Why?
| | Copper | 1 | 2015 | 99 | 0.030 |
Why?
| | Bacteriophages | 1 | 2015 | 75 | 0.030 |
Why?
| | Substance Abuse Treatment Centers | 2 | 2009 | 40 | 0.030 |
Why?
| | Protein Transport | 1 | 2015 | 391 | 0.030 |
Why?
| | Computer Simulation | 1 | 2018 | 873 | 0.030 |
Why?
| | Bacterial Proteins | 2 | 1989 | 735 | 0.030 |
Why?
| | Alcoholism | 1 | 2000 | 710 | 0.030 |
Why?
| | Patient Care Team | 1 | 1998 | 517 | 0.030 |
Why?
| | Antibodies | 1 | 2015 | 365 | 0.030 |
Why?
| | HIV Infections | 1 | 2007 | 2453 | 0.030 |
Why?
| | Oxidative Stress | 1 | 2019 | 1068 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 787 | 0.030 |
Why?
| | Membrane Proteins | 2 | 1989 | 1016 | 0.030 |
Why?
| | Blotting, Western | 1 | 2015 | 1143 | 0.030 |
Why?
| | Genetic Testing | 1 | 2015 | 381 | 0.030 |
Why?
| | Mandatory Programs | 1 | 2012 | 14 | 0.030 |
Why?
| | Patient Satisfaction | 1 | 1996 | 571 | 0.030 |
Why?
| | Ethanol | 1 | 1997 | 534 | 0.030 |
Why?
| | Patient Compliance | 1 | 1996 | 524 | 0.030 |
Why?
| | Thioredoxins | 1 | 2012 | 33 | 0.020 |
Why?
| | Risk-Taking | 1 | 2015 | 333 | 0.020 |
Why?
| | Age Factors | 1 | 1999 | 2885 | 0.020 |
Why?
| | Amino Acids | 1 | 2015 | 445 | 0.020 |
Why?
| | United States | 1 | 2008 | 12137 | 0.020 |
Why?
| | Atomoxetine Hydrochloride | 1 | 2010 | 4 | 0.020 |
Why?
| | Adrenergic Uptake Inhibitors | 1 | 2010 | 13 | 0.020 |
Why?
| | Interview, Psychological | 1 | 2010 | 85 | 0.020 |
Why?
| | Genetic Complementation Test | 1 | 2009 | 62 | 0.020 |
Why?
| | Drug Delivery Systems | 1 | 2012 | 295 | 0.020 |
Why?
| | Temperature | 1 | 2012 | 564 | 0.020 |
Why?
| | Checklist | 1 | 2010 | 84 | 0.020 |
Why?
| | Transcription, Genetic | 1 | 1995 | 1310 | 0.020 |
Why?
| | Diagnostic and Statistical Manual of Mental Disorders | 1 | 2010 | 230 | 0.020 |
Why?
| | Community Mental Health Centers | 1 | 2009 | 13 | 0.020 |
Why?
| | Gene Deletion | 1 | 2009 | 356 | 0.020 |
Why?
| | Social Work | 1 | 2009 | 74 | 0.020 |
Why?
| | Multicenter Studies as Topic | 1 | 2009 | 249 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2010 | 1656 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2009 | 926 | 0.010 |
Why?
| | Disease Progression | 1 | 2011 | 2371 | 0.010 |
Why?
| | Age Distribution | 1 | 2004 | 341 | 0.010 |
Why?
| | Sex Distribution | 1 | 2004 | 336 | 0.010 |
Why?
| | Ambulatory Care | 1 | 2007 | 479 | 0.010 |
Why?
| | Smoking Prevention | 1 | 2004 | 157 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2009 | 1204 | 0.010 |
Why?
| | Counseling | 1 | 2006 | 342 | 0.010 |
Why?
| | Models, Biological | 1 | 2009 | 1611 | 0.010 |
Why?
| | Wechsler Scales | 1 | 1996 | 52 | 0.010 |
Why?
| | Sampling Studies | 1 | 1996 | 92 | 0.010 |
Why?
| | RNA Probes | 1 | 1995 | 13 | 0.010 |
Why?
| | Blotting, Southern | 1 | 1995 | 68 | 0.010 |
Why?
| | Intelligence | 1 | 1996 | 130 | 0.010 |
Why?
| | Mood Disorders | 1 | 1996 | 112 | 0.010 |
Why?
| | Chi-Square Distribution | 1 | 1996 | 492 | 0.010 |
Why?
| | Aggression | 1 | 1996 | 181 | 0.010 |
Why?
| | Time Factors | 1 | 2004 | 6077 | 0.010 |
Why?
| | Genotype | 2 | 1989 | 1757 | 0.010 |
Why?
| | Analysis of Variance | 1 | 1996 | 1218 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2004 | 4595 | 0.010 |
Why?
| | Incidence | 1 | 1997 | 2314 | 0.010 |
Why?
| | Transformation, Bacterial | 1 | 1989 | 5 | 0.010 |
Why?
| | SEC Translocation Channels | 1 | 1989 | 10 | 0.010 |
Why?
| | Restriction Mapping | 1 | 1989 | 77 | 0.010 |
Why?
| | Lac Operon | 1 | 1989 | 44 | 0.010 |
Why?
| | DNA Restriction Enzymes | 1 | 1988 | 54 | 0.000 |
Why?
| | Genes | 1 | 1988 | 223 | 0.000 |
Why?
| | Cross-Sectional Studies | 1 | 1997 | 4402 | 0.000 |
Why?
|
|
Riggs's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|